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Abstract: Neonatal sepsis is still a leading cause of death among newborns. Therefore a 
protein-microarray  for  point-of-care  testing  that  simultaneously  quantifies  the  sepsis 
associated serum proteins IL-6, IL-8, IL-10, TNF alpha, S-100, PCT, E-Selectin, CRP and 
Neopterin has been developed. The chip works with only a 4 µ L patient serum sample and 
hence minimizes excessive blood withdrawal from newborns. The 4 µ L patient samples are 
diluted with 36 µ L assay buffer and distributed to four slides for repetitive measurements. 
Streptavidin coated magnetic particles that act as distinct stirring detection components are 
added, not only to stir the sample, but also to detect antibody antigen binding events. We 
demonstrate that the test is complete within 2.5 h using a single step assay. S-100 conjugated 
to  BSA  is  spotted  in  increasing  concentrations  to  create  an  internal  calibration.  The 
presented low volume protein-chip fulfills the requirements of point-of-care testing for 
accurate and repeatable (CV < 14%) quantification of serum proteins for the diagnosis of 
neonatal sepsis.  
Keywords:  protein  microarray;  streptavidin  coated  magnetic  particles;  miniaturization; 
point-of-care testing; neonatal sepsis; internal calibration 
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1. Introduction  
Sepsis is a life-threatening systemic body infection manifested by symptoms ranging from elevated 
heartbeat, breathing difficulties and fever to severe necrosis of the internal organs. It is caused by 
microbial pathogens including bacteria, virus and fungi. The survival rates increase enormously with 
an early stage diagnosis which allows timely administration of antibiotics. Neonatal sepsis is still a 
leading cause of death among newborns since symptoms are often wrongly interpreted due to their 
unspecific and late occurrence [1]. However, early-stage diagnosis in neonates is even more challenging 
and demands for a reliable and rapid point-of-care device that works with a low sample volume to 
keep invasive procedures on neonates to a minimum. Key requirements for point-of-care devices relate 
to short assay time, quality assurance through simple and stable calibration, convenient operation and 
cost  effectiveness  [2].  The  standard  diagnosis  procedure  for  sepsis  is  based  on  the  isolation  of 
microorganisms from patient blood or urine samples and subsequent microbiological cultivation and 
identification. Disadvantages of the standard procedures are the low sensitivity, the processing time 
which may exceed 24 hours and the need for large sample volumes (>1 mL) [3–5]. 
Sepsis is a condition caused by pathogenic microorganisms but induced by the immune response 
through excessive release of growth factors, cytokines and inflammation- and coagulation factors into 
the systemic circulation. Those factors can be exploited as specific biomarkers enabling early and 
reliable  diagnosis.  The  cytokines  interleukin  6  (IL-6),  interleukin  8  (IL-8),  interleukin  10  (IL-10)  
and  tumor  necrosis  factor  alpha  (TNF  alpha)  and  the  serum  proteins  C-reactive  protein  (CRP), 
procalcitonin (PCT), S-100 and E-Selectin have been identified as a specific and accurate biomarker 
panel for the early diagnosis of sepsis. The clinically relevant ranges as well as the cut-off values of the 
respective  serum  proteins  that  allow  discrimination  between  healthy  and  septicaemic  patients  are 
outlined in Table 1. IL-6, IL-8, IL-10 and TNF alpha are proinflammatory cytokines secreted by cells 
of the immune system that mediate host defense [6,7]. E-Selectin is expressed by endothelial cells and 
is a main mediator in the migration of immune cells to the centre of infection [8]. CRP and PCT are  
acute-phase  reactants  expressed  predominately  as  part  of  the  immediate  immune  response  to  
infections [9]. S-100 serum levels are significantly elevated in neuronal inflammations [10]. Neopterin 
is expressed by macrophages in response to infections [11]. 
Table 1. Cut-off values for the respective biomarkers. 
Biomarker  Cut-off values  Biomarker  Cut-off values 
IL-6 (pg/mL)  18 [7], 31 [6]  PCT (pg/mL)  500 [9], 36 [13] 
IL-8 (pg/mL)  20 [12]  Neopterin (pg/mL)  16 [11] 
IL-10 (pg/mL)  17 [13]  S-100 (ng/mL)  10.4 [10] 
TNF alpha (pg/mL)  17 [6]  CRP (µ g/mL)  10 [7,9] 12 [6] 
E-Selectin (ng/mL)  174 [6]     
Herein we aim at the further development of a sepsis chip for point-of-care testing of neonatal 
sepsis. This is achieved by: (a) the reduction of required patient sample volume, (b) the reduction of 
assay  steps  and  incubation  times  and  (c)  the  integration  of  an  internal  calibration.  The  chip  for 
biomarker  detection  of  sepsis  comprises  multi-analyte  on-chip  immunoassays  which  include  both 
sandwich (cytokines, PCT, S-100, E-Selectin) and binding inhibition formats (CRP, neopterin). The Sensors 2012, 12                         
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combination of both assay formats allows analysis of the selected biomarkers on one chip despite the 
large  heterogeneity  of the  analytes regarding cut-off concentration [14]. In  our  previous work we 
showed that LODs of 15 pg/mL (IL-6), 36 pg/mL (IL-8), 65 pg/mL (IL-10), 40 pg/mL (TNF alpha), 
0.078 ng/mL (PCT), 0.46 ng/mL (neopterin) and 3 µ g/mL (CRP) are achieved in this set-up [14].  
In  order  to  prevent  excessive  blood  withdrawal  from  newborns,  the  biochip  was  further 
miniaturized  to  operate  with  a  five-fold  reduced  sample  volume.  The  assay  performance  of  the 
miniaturized chip is then compared with the classical format and evaluated using assay parameters like 
analyte  concentration  halfway  between  the  zero  point  and  the  upper  asymptote  (IC50),  limit  of 
detection (LOD), limit of quantification (LOQ), and inter- and intra-array variations.  
In general, assay miniaturization provokes loss in assay sensitivity due to e.g., diffusion limitations. 
While a sample volume of 50 µL, as used for the classical chip, is mixed properly during incubation on 
the rotational shaker, a sample volume of 10 µL, as used for the miniaturized chip, is too small to be 
moderately  mixed  under  the  same  incubation  conditions.  Different  theoretical  considerations  have 
been made concerning the impact of diffusion on the antibody antigen kinetics for immunoassays on 
solid  surfaces  [15–17].  For  example,  Kusnezow  et  al.  [15]  developed  a  mathematical  model  to 
simulate  the  impact  of  diffusion  on  the  binding  kinetics.  This  model  was  examined  empirically 
comparing the development of signal intensities over time for anti-IFN- spots of 45 µm to 272 µm 
radius  under  stirring  and  non-stirring  conditions.  Clearly,  stirring  significantly  accelerates  the 
immunoreaction (up to hundreds of times), while the velocity increases with decreasing size of the 
spot.  Hartmann  et  al.  reported  three-fold  enhanced  signals  using  surface  acoustic  waves  (SAW) 
coupled through the glass slide into the reaction solution. To account for the antibody spot kinetics, 
thus the migration of the analytes in solution towards the spot and across the surface we included  
bi-functional streptavidin coated magnetic particles (Strep.MPs), which act as both micro-mixer and 
detection reagent for the biotinylated antibodies. Strep.MPs in the sizes of 130 nm, 500 nm and 1 µm 
were  tested.  In  addition,  the  assay  procedure  was  further  optimized  by  reducing  assay  steps  and 
incubation  times.  Furthermore  the  calibration  was  integrated  on  the  chip  (internal  calibration) 
presenting a point-of-care device suitable for use in neonates.  
2. Experimental Section 
2.1. Materials and Reagents 
Chip platform used was the proprietary ARChip Epoxy [14], Anti IL-6 (MQ2-13A5), recombinant 
IL-6 protein, biotinylated anti IL-6 (MQ2-39C3) as well as anti IL-10 (JES3-9D7), recombinant IL-10, 
biotinylated  anti  IL-10  (JES3-12G8),  anti  TNF  alpha  (MAb1),  recombinant  TNF  alpha  and 
biotinylated TNF alpha (MAbF6C5) were purchased from eBioscience (San Diego, CA, USA). Anti  
S-100  (MAb8B10),  S-100  protein,  biotinylated  anti  S-100  (MAb6G1),  anti  PCT  (MAb16B5), 
biotinylated anti PCT (MAb42) and CRP-free serum were obtained from Hytest (Turku, Finland). Anti 
E-Selectin,  human  E-Selectin,  biotinylated  anti  E-Selectin  were  purchased  from  R&D  Systems 
(Minneapolis, MN, USA). Anti CRP (C5) and biotinylated anti CRP (C7) were from Exbio (Vestec, 
Czech Republic). Human procalcitonin was obtained from ProSpec-Tany TechnoGene Ltd. (Rehovot, 
Isreal). Neopterin conjugated with bovine serum albumin (BSA) and antibodies mAb 3E2 were kindly Sensors 2012, 12                         
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provided by Milan Franek, Veterinary Research Institute,  Brno, Czech Republic and labelled with 
Dy647 by Exbio. Dy647 Streptavidin was from Dyomics (Jena, Germany) and Cy3-Streptavidin was 
from GE  Healthcare (Chalfont St  Giles, UK).  Streptavidin  coated magnetic particles with a 1 µ m 
diameter were purchased from Roche (Basel, Switzerland), Streptavidin coated magnetic particles with 
a 500 nm and a 130 nm diameter were from Spherotech Inc. (Lake Forest, IL, USA) and magnetic 
particles  with  a  500  nm  diameter  were  from  micromod  (Rostock-Warnemuende,  Germany). 
Biotinylated anti Cy3/Cy5 (Cy-96), Tween 20, CHAPS, glycidyloxypropyltrimethoxysilane (GOPS), 
polyethylenglycol, MW 6000 (PEG 6000), ethanolamine and sodium deoxycholate were purchased 
from Sigma (St. Louis, MO, USA). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) was from 
Fluka Biochemicals (St. Louis, MO, USA). Phosphate buffered saline (PBS, pH 7.2) was purchased 
from Gibco (Invitrogen, Grand Island, NY, USA) and MES buffered saline packs were from Thermo 
Fisher Scientific (Portsmouth, NH, USA).  
2.2. Dy647 Streptavidin Conjugation to Magnetic Nanoparticles 
All  washing  steps  were  performed  via  centrifugation  at  16,200  g-force  number  for  6  min 
(Eppendorf Centrifuge 5417C). Five hundred µ L of a 1 mg/mL 500 nm magnetic particles suspension 
are coated with functionalized silica by adding 200 µ L GOPS and sonicating for 90 min, then an 
additional 10 µ L of GOPS was added and the particles were sonicated (Branson Ultrasonics B.V. 2510, 
Soest,  The  Netherlands)  for  another  90  min.  The  particles  were  washed  twice  with  1×   PBS  and 
resuspended in 1×  PBS. Particles were washed 3×  with 0.5 mM MES buffer (pH 5.0) by centrifugation 
and  resuspended  in  250  µ L  MES  buffer.  50  µ L  Dy647-streptavidin  (1  mg/mL  Stock)  and  50  µ L  
PEG 6000 were added and incubated for 2 h on a rotational shaker at maximum speed (Stovall, USA). 
The reaction was vortexed every 30 min. The particles were washed twice with PBS and resuspended 
in 30 mM ethanolamine containing 1% BSA for 30 min to quench the reaction. The particles were 
washed 3×  and resuspended in 500 µ L 1×  PBS containing 0.05% Tween 20 and 0.1% BSA (pH 7.4) and 
stored at 4 ° C until use. The particle concentration was estimated to be 200 µ g/mL. The protocol was 
adapted from [18].  
2.3. Chip Fabrication 
Capture antibodies were diluted in printing buffer “na” (1× PBS (pH 7.2)/0.01% Na-deoxycholate) 
to  concentrations  of  0.4  µ g/mL  for  IL-6,  IL-8,  IL-10  and  0.5  µ g/mL  for  TNF  alpha,  S-100, 
procalcitonin and E-Selectin. The proteins CRP and neopterin conjugated to BSA were diluted in 
printing buffer “cb” (1× PBS (pH 7.2)/0.005% CHAPS, 0.01% BSA) to concentrations of 0.5 mg/mL 
each. The appropriate spotting conditions (composition of print buffer, humidity during spotting and 
antibody  concentration)  were  established  in  previous  research  [19].  The  proteins  were  arrayed  on 
proprietary ARChip Epoxy slides using the Omnigrid contact spotter from GeneMachines (pin SMP3). 
The spot-to-spot distance was 350 µm. Each of the probes was spotted in triplicates in 12 identical 
arrays at a relative humidity of 50%. To allow full immobilization of the probes the slides were kept  
at 4 ° C for at least three days. 
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2.4. Internal Calibration Curve 
S-100 protein was conjugated to BSA to improve immobilization on ARChip Epoxy. The conjugate 
was prepared by incubating 100 µ L S-100 (0.5 mg/mL Stock) with 1 mg EDC for 10 min on an orbital 
shaker. An additional 10 µ L BSA (5 mg/mL) were added and the reaction was allowed to proceed  
for 4 h. Zero to 218.7 ng/mL S-100-BSA-conjugate in buffer “cb” was then spotted onto the chip.  
2.5. Chip Processing 
Surface blocking was performed for 30 min in 1×  PBS (pH 7.2)/0.1% Tween 20 in order to remove 
any unbound probes and to deactivate reactive surface groups. Slides were washed twice in 1×  PBS 
(pH  7.2)  and  dried  using  compressed  air.  Assay  buffer  used  consists  of  CRP  free  human  serum  
and  0.1  M  Tris  (pH  7.4),  10  mM  CaCl2,  100  mM  NaCl,  0.1%  Tween  in  a  ratio  of  1:10.  This 
corresponds to 20 µ L patient serum sample diluted with 180 µ L Tris buffer for the classical chip  
and 4 µ L patient serum sample diluted with 36 µ L Tris buffer for the miniaturized chip.  
2.5.1. Classical Chip 
The  protocol  of  the  “classical  sepsis  chip”  has  been  introduced  before  [14].  Briefly,  for  one 
experiment a 4-slide set was mounted into the FastFrame (Whatman) to generate 4 ×  12 array fields  
(7 mm ×  7 mm each). This set accomodates 12 replicate measurements (four arrays with three replicate 
spots each) of nine point calibration standards and three “patient samples”, which are distributed on the 
slides taking into account the variation of production parameters. Each array was incubated with either 
50 µ L diluted sample or a calibration standard for 2.5 h.  
Calibration standards were prepared by serial dilution of mixes of analytes in CRP-free serum and 
diluted with assay buffer 1:10. For the so called “external calibration” nine spiked standards were 
applied.  After  washing  three  times  with  1×   PBS  (pH  7.2)/0.1%  Tween-20,  slides  were  incubated  
for 45 min with 50 µ L biotinylated antibody mixes with end concentrations of 1 µ g/mL each. After 
washing  three  times,  slides  were  incubated  with  4  µ g/mL  Dy647  streptavidin  for  45  min.  All 
incubation  steps  were  carried  out  on  the  orbital  shaker  (Stovall)  at  maximum  speed  at  room 
temperature. Slides were washed and dried using compressed air and stored in the dark until scanning. 
2.5.2. Miniaturized Chip 
While the classical chip was processed in the FastFrame that provides wells that are 7 mm in length 
and  width  the  low  volume  chip  was  arranged  in  silicon  miniwells  (GraceBio  Laboratories,  city, 
country)  with incubation chambers of 4.5  mm in  diameter. Those  wells  were  small enough for a 
sample of 10 µ L to completely cover the wells harboring the arrays. 10 µ L patient serum sample or 
standard dilution series diluted 1:10 with assay buffer was incubated for 2.5 h in a humid chamber on 
the magnetic stirrer (Variom, Poly 15) at 450 rpm to allow sample mixing. The standard dilution series 
was  spiked  with  appropriate  amounts  of  antigen,  biotinylated  antibodies  (1  µ g/mL)  and  strep.MPs.  
(4 µ g/mL). Detection occured via labeling with a biotinylated antibody against Cy3/Cy5 and Cy3 
labeled streptavidin (1 µ g/mL each). Slides were washed and dried using compressed air and stored in the 
dark until scanning. Sensors 2012, 12                         
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2.6. Fluorescence Scanning 
Fluorescence  signals  (λex:  635  nm,  λem:  670  nm)  were  recorded  using  the  Genepix  4000B  
non-confocal  scanner  (Axon  Instruments,  Sunnyvale,  CA,  USA).  Data  were  analyzed  with  the  
Genepix 6.0 software. The photomultiplier tube (PMT) voltage was held constant throughout the scans 
for each analyte to allow data comparison. 
2.7. Data Analysis 
The mean signal values were calculated from 12 replicates and were background corrected. Data 
that were out of the mean signal values ±  the standard deviation (SD) were excluded. Standard curves 
were set up with GraphPad Prism 5.0 using the five parameter logistic fit.  
The IC50 value (also reported as ED50) is defined as the concentration halfway between the zero 
point and the upper asymptote when the value of the asymmetric factor is 1. The limit of detection 
(LOD) is defined as lowest concentration that can be detected and was calculated by the mean zero 
concentration + three standard deviations (SD) of the blank [20]. The limit of quantification (LOQ) 
was defined as the lowest analyte concentration that could be reliably and quantitatively determined 
and was calculated by the mean zero concentration + 10 standard deviations of the blank [20]. The 
inter-array variability refers to the variation between the arrays (CVinter% = SD/mean ×  100) and the 
intra-array variability to the variation within one array (CVintra% = SD of one triplicate/mean of one 
triplicate ×  100). Recoveries were calculated to identify the accuracy of the assay displaying the % 
relation between the calculated concentrations and the expected concentrations.  
3. Results and Discussion  
3.1. Comparison of Chip Formats: Classical versus Miniaturized 
To  prevent  excessive  blood  withdrawal  from  newborns  the  sepsis  chip  was  miniaturized  by 
applying a fivefold reduced sample volume. The main challenge in the realization of the miniaturized 
protein chip was developing the appropriate incubation and stirring system to maintain good assay 
performance with respect to sensitivity, reproducibility and accuracy. IC50 values, CVs and LODs of 
the resulting calibration curves were defined as criteria for assay performance. The assay designs used 
in the classical and miniaturized chip are presented in Figure 1. Figure 1(a) shows the classical chip 
format: 20 µ L of patient serum sample diluted with 180 µ L assay buffer are incubated and analyte 
concentrations  are  detected  by  incubating  biotinylated  detection  antibodies  and  Dy647-labeled 
streptavidin. Three incubation steps are necessary to accurately run the classical chip resulting in an 
entire incubation time of 4 h. Figure 1(b) presents the miniaturized chip format: only 4 µ L of patient 
serum sample diluted with 36 µ L assay buffer are required to accurately run the assay with a four-fold 
replication. Strep.MPs are implemented in the assay for two reasons: first, to stir the small volumes 
during sample incubation, and secondly, to act as a detection reagent when bound to the biotinylated 
secondary antibodies. In the second incubation step biotinylated antibody against Cy3/Cy5 and Cy3 
labeled Streptavidin are added. Hence, only two incubation steps are necessary to accurately run the 
miniaturized chip resulting in an entire incubation time of 3 h and 15 min. 
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Figure  1.  On-chip  sandwich  immunoassay  steps  for  (a)  the  classical  chip  (b)  the 
miniaturized  chip  and  (c)  the  optimized  miniaturized  chip.  Capture  antibodies  are 
immobilized equally providing same array format for the classical chip and the miniaturized 
chip.  a(I)  incubation  of  analytes  (2.5  h),  a(II)  incubation  of  biotinylated  detection 
antibodies (45 min), a(III) detection of bound antigens/antibodies via Dy647 Streptavidin 
incubation (45 min); b(I) Incubation of analytes, biotinylated antibodies and streptavidin 
conjugated magnetic particles in one step (2.5), b(II) detection via biotinylated antibody 
against Cy3/Cy5 and Cy3 labeled streptavidin; c(I) Incubation of analytes, biotinylated 
antibodies and Dy647 Streptavidin conjugated magnetic particles in one step (2.5 h). 
 
Figure 2 shows the standard curves obtained for S-100, IL-6, CRP and E-Selectin when comparing 
the  assay  performance  of  the  classical  chip  (50  µ L)  with  the  miniaturized  chip  (10  µ L  without 
strep.MPs). The IC50 value was taken as evaluation parameter since it lies within the ascending slope 
providing the highest precision of the measurement and a good reference point for comparison of 
different  treatments.  For  the  classical  chip  the  IC50  values  for  IL-6,  S-100,  E-Selectin  and  CRP  
are 46 pg/mL, 10 ng/mL, 170 ng/mL and 4.7 µ g/mL respectively, while for the miniaturized chip they 
were 82 pg/mL, 19 ng/mL, 202 ng/mL and 2.5 µ g/mL. This demonstrates that reduction of the sample 
volume leads to losses in sensitivity. Obviously, sample volumes of 10 µL are too small to be properly 
mixed on the orbital shaker during incubation. Thus, strep.MPs were implemented as so-called stirring 
detection reagents in the assay to accelerate the antibody antigen kinetics. Acceleration of diffusion 
processes is a common issue and magnetic particles have been previously outlined as successful tool to 
provide sample mixing in microscale devices [21, 22]. In optical biochips, Heer et al. [23] reported up 
to a four-fold enhancement of fluorescent signals upon controlled movement of magnetic microspheres 
in the DNA hybridization buffer, while Smith et al. [18] used antibody-labeled magnetic particles to 
pre-concentrate the target via magnetic separation and integrate them as a tracer in the immunoassay. Sensors 2012, 12                         
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Oligonucleotide- [24] and antibody-labelled [25] magnetic particles were also used in magneto-resistive 
biochips. In our assay strept.MPs were implemented to firstly, achieve effective sample mixing and 
secondly, to measure antigen antibody binding events using fluorescence detection. Figure 2 shows the 
calibration curves obtained when adding strep.MPs to the test solution (10 µ L). The assay performance 
was significantly enhanced in terms of the assigned IC50 values (16.5 pg/mL, 4.3 ng/mL, 105 ng/mL 
and 4.4 µ g/mL for IL-6, S-100, E-Selectin and CRP).  
Figure 2. Calibration curves for (a) IL-6 (b) S-100 (c) E-Selectin and (d) CRP. The black 
curve ( ) displays the 10 µ L assay and the red curve ( ) shows the 50 µ L assay when 
adding strep.MPs; the blue curve ( ) displays the classical 50 µ L assay and the green 
curve ( ) displays the 10 µ L assay without addition of strep.MPs. 
 
Nano-sized and micro-sized strep.MPs (130 nm, 500 nm and 1 µ m) were applied to the miniaturized 
assay to assess potential concerns about steric hindrance, but the assay performance was similar no 
matter what particle size was used.  
Comparison of the miniaturized protein chip with and without strep.MPs shows that sensitivity is 
increased by a factor of 2 (for E-Selectin and CRP) to 4 (for IL-6 and S-100) through the addition of 
strep.MPs. In Section 3.2.1 this method will be further advanced in that fluorescent strep.MPs will be 
implemented as stirring detection reagent. 
3.2. Optimization of the Miniaturized Chip 
3.2.1. Reducing Assay Steps 
As outlined in Figure 1 the classical 50 µ L chip (a) requires three separate incubation steps whereas 
the miniaturized bio-chip (b) requires only two incubation steps. In order to optimize the low volume 
chip the assay was performed in one step only (Figure 1(c)). This means that analytes, biotinylated Sensors 2012, 12                         
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antibodies  and  streptavidin  coated  magnetic  particles  were  incubated  simultaneously  on  the  chip.  
Sauer et al. [14] showed that in the classical 50 µL format the assay performance of an “all-in-one-step” 
assay was significantly deteriorated compared to the three step assay. However, this does not apply to 
the new low volume chip, since this protocol incorporates strep.MPs which strongly promote mixing 
of the solution and analyte binding. Still, the detection step (Figure 1(b-II)) of the miniaturized biochip 
is quite complex. Therefore, magnetic particles were conjugated with dye labeled streptavidin in order 
to completely replace the second incubation step. Figure 2 compares the assay performance of the 
optimized  low  volume  assay  (black  curve)  with  the  classical  assay  (red  curve)  showing  that  the 
standard  deviations,  the  inflection  point  and  the  maximal  signals  of  the  curves  are  similar.  This 
indicates  that  reducing  the  number  of  assay  steps  has  no  impact  on  the  assay  sensitivity  and 
reproducibility of results. The new low volume assay accomplishes within 2.5 h providing an accurate 
“all-in-one-step” assay for point-of-care diagnostics of sepsis-relevant biomarkers. 
3.2.2. Optimizing Incubation Time 
To guarantee a fast and effective treatment of the disease, a rapid diagnosis and thus short assay 
times are essential. However, in order to achieve short assay times, a compromise must be made 
between incubation time, assay sensitivity and data reproducibility. In order to determine the lowest 
incubation time necessary to perform a sensitive and accurate chip analysis three different incubation 
times were tested and evaluated using IC50, CV and LOD as measures for the assay performance. 
While for the detection of IL-6, S-100 and E-Selectin sandwich immunoassays were performed, a 
binding inhibition test was done  for CRP.  Figure  3 shows the calibration  curves for IL-6, S-100,  
E-Selectin and CRP obtained with the low volume chip described in Section 3.2.1 after 1.5 h, 2 h  
and 2.5 h “all-in-one” incubation.  
Figure  3.  Calibration  curves  for  (a)  IL-6  (b)  S-100  (c)  E-Selectin  and  (d)  CRP  in  
human serum 1:10 diluted with assay buffer after 2.5 h ( ), 2 ( ) and 1.5 h ( ) 
processing time. 
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Figure 3 indicates that the effect of incubation time on the calibration curves is similar for all 
analyzed biomarkers. A decrease of incubation time provokes a loss in sensitivity which can be seen 
from the shift of calibration curve to higher analyte concentrations, reduced fluorescence signals and 
increased IC50 values. IC50 values are listed in Table 2 together with LODs and CVs. While sensitivity 
expressed by LOD, LOQ and IC50 is similar for IL-6 and E- Selectin after 2 h and 2.5 h incubation, 
there are significant differences observed for S-100 and CRP. Sensitivity was drastically reduced for 
all tested biomarkers, if incubated for only 1.5 h. Interestingly, reproducibility of data was not affected 
and remained the same (CV < 14%) regardless what incubation time or analyte was used.  
Table 2. Assay parameters for IL-6, S-100, E-Selectin and CRP obtained after 2.5 h, 2 h 
and 1.5 h incubation. 
Analyte  IL-6 (pg/mL)  S-100 (ng/mL)  E-Selectin (ng/mL)  CRP (µ g/mL) 
Time  2.5 h  2 h  1.5 h  2.5 h  2 h  1.5 h  2.5 h  2 h  1.5 h  2.5 h  2 h  1.5 h 
LOD  1.1  1.2  149.0  0.7  1.8  5.0  4.0  6.3  30.1  0.10  0.27  0.48 
LOQ  6.4  7.0  151.5  1.6  7.1  14.7  12.6  11.4  41.7  0.22  0.42  0.87 
IC50  68  70  152  9  15  43  31  30  96  30  64  138 
CV (%)  11  10  14  10  8  14  11  12  11  10  11  13 
In summary, a 2 h incubation step is most likely sufficient for the  diagnosis of neonatal sepsis. 
While  assay  sensitivity  remains  unchanged  for  IL-6  and  E-Selectin,  assay  sensitivity  is  slightly 
decreased for S-100 and for CRP. For diagnostic purposes the right balance between incubation time 
and sensitivity has to be specified individually according to the clinical requirements. 
3.3. Quantification of “Patient” Samples 
The optimized low volume protein chip as described in Section 3.2 was tested for quantification of 
“patient” samples and evaluated in a recovery experiment. The assay performance was assessed by 
recovery values calculated as the relation of interpolated and expected concentrations. Recoveries that 
lie  within  70  and  130%  are  considered  as  acceptable  in  clinical  diagnosis  indicating  reasonable 
accuracy of the assay [26]. Three “patient” samples with known clinically relevant concentrations of 
IL-6,  S-100,  E-Selectin  and  CRP  were  applied  additionally  to  the  standard  dilution  series.  The 
concentrations of all “patient” samples were chosen to comply with real patient serum samples. Each 
analyte was tested in 3 different concentrations ranging from low to high clinically relevant values to 
cover the whole notable range.  
Mean intra-array variations of 11.8%, 10.3%, 12.4% and 13.3% for IL-6, S-100, E-Selectin and 
CRP respectively are obtained. Average inter-array variability of the four tested markers was 11.7% 
which indicates a good chip-to-chip reproducibility. Figures of merit are summarized in Table 3. High 
accuracy (within 70 to 130%) is obtained for concentrations within the ascending part of the slope 
whereas  recoveries  obtained  for  especially  low  or  high  concentrations  are  out  of  the  clinically 
acceptable range.  
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Table 3. Recoveries, LODs, LOQs and inter- and intra-array variabilitiy for the optimized 
low volume assay. 
Biomarker  Concexp  Conccalc  Recovery (%)  LOD  LOQ  CVinter (%)  CVintra (%) 
IL-6  
(pg/mL) 
1.50  1.2  79 
1.2  6.5  10.7  11.8  7.5  6.6  88 
37.5  64.5  172 
S-100 
(ng/mL) 
0.50  - (*)  - 
0.89  5.3  10.0  10.3  2.5  1.7  69 
12.5  11.7  94 
E-Selectin 
(ng/mL) 
4.50  4.2  92 
2.7  4.5  12.2  12.4  22.5  16.8  75 
112.5  103.0  92 
CRP  
(µ g/mL) 
0.5  1.0  200 
0.13  0.32  14.0  13.3  2.5  2.6  102 
12.5  - (*)  - 
(*) out of the range of the calibration curve. 
3.4. Internal Calibration Curve 
For calibration of the protein microarray and quantification of the unknown sample a standard 
dilution series was prepared for each assay (external calibration). To do so, nine spiked antigen mixes 
replicated four times were applied to 36 wells. This leaves 12 wells for patient samples (e.g., three 
samples, four replicates) when using a set of four slides. To reduce the effort and further simplify the 
protein-chip the calibration was directly integrated on the chip (internal calibration). Several attempts 
to provide a one patient, one biochip format have been made by immobilization of the protein [27] or 
the detection components [28] in increasing concentrations. In our approach S-100 was conjugated to 
the carrier protein BSA and subsequently immobilized in increasing concentrations on ARChip Epoxy 
forming  an  internal  calibration.  The  array  of  the  immobilized  BSA-S-100  conjugate  and  specific 
capture  antibodies  was  then  reacted  with  the  unknown  sample,  biotinylated  secondary  antibodies  
and 500 nm Dy647-strep.MPs as schematically shown in Figure 2(c). Chip performance of the internal 
and external calibration curve was compared. As can be seen from Figure 4, both internal and external 
calibration curves are very similar in terms of shape, measurement range and sensitivity as defined by 
the slope of the curve which demonstrates the suitability of the approach. Nevertheless an internal 
standard curve is advantageous over an external curve as it needs less reagents and shorter handling 
time and allows faster availability of test results: while quantification via an external calibration curve 
requires nine wells per slide and one well for the sample of interest, integration of an internal standard 
curve reduces the number of wells per slide to only one well, the sample well.  
Figure 4(a) compares the curves obtained for the internal and external calibration, and Figure 5 
shows a typical fluorescence image of processed calibration spots. The image demonstrates the high 
quality of the arrayed spots which is depicted by the regular spot morphology, the concise shape and 
the even distribution within the spot. This is also reflected in the good reproducibility of biomarker 
measurement as can be seen from Table 3: the coefficient of variation is ≤14%.  Sensors 2012, 12                         
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Figure 4. Calibration curves (a) and Scatter plot (b) for the internal ( ) and external chip 
calibration ( ). Internal and external calibration curves cover a very similar measurement 
range  and  most  fluorescence  intensity  values  cluster  within  the  95%  confidence  band  
(grey dotted lines) of the fit line. The coefficient of determination (R
2) was 0.968. 
 
Figure  5.  Processed  chip  showing  spots  obtained  for  the  external  (a)  and  internal  
(b) calibration at a concentration of 8.1 ng/mL S-100. 
 
The calibration curves are almost identical both in terms of shape and maximal signal intensities 
which is in accordance with the assay parameters obtained (internal calibration: LOD 0.239 ng/mL,  
LOQ  1.152  ng/mL,  IC50  3.38  ng/mL,  CVinter  12%;  external  calibration:  LOD  0.241  ng/mL,  
LOQ 0.976 ng/mL, IC50 2.84 ng/mL, CVinter 13%). Figure 4(b) depicts the correlation and precision 
between internal and external calibration. The fluorescence signals obtained for the external calibration 
are plotted against the fluorescence signals from the internal calibration. A strong linear correlation 
(coefficient  of  determination  (R
2)  of  0.968)  was  observed:  most  values  cluster  within  the  95% 
confidence band (grey dotted lines) of the fit line. The significance of the linear correlation is confirmed 
by a p-value below 0.01%. The mean intra-array variation was 10.4% for the external and 10.8% for the 
internal calibration. 
Additionally to the standard dilution series “patient” samples with known analyte concentrations 
(2.5 ng/mL and 12.5 ng/mL) were processed on the chip to evaluate the accuracy of the calibration 
curves calculated from the %-relation between interpolated concentrations and expected concentrations. 
The recoveries obtained were 70% and 103% when interpolating to the external calibration and 70% 
and 83% when interpolating to the internal calibration. The recoveries are within 70–130% which is 
appropriate for clinical purposes.  
4. Conclusions  
We have presented herein a protein chip that fulfills the requirements for point-of-care diagnostics 
in terms of miniaturization, assay time and internal calibration. A sample volume of 40 µ L which Sensors 2012, 12                         
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corresponds to 4 µ L patient serum sample diluted 1:10 with assay buffer is sufficient to quantify sepsis 
associated serum proteins. The optimized low volume chip is especially attractive for diagnosis in 
neonates since the reduced sample volume minimizes stress and pain caused through excessive blood 
withdrawal.  Sample  mixing  to  overcome  diffusion  limitations  is  ensured  through  the  addition  of 
streptavidin coated magnetic particles (strep.MPs) acting as both stirring and detection components. 
Fluorescence labeling of the streptavidin coated magnetic particles further accelerates and simplifies 
the assay assembly resulting in a single step assay that is accomplished within 2.5 h. We demonstrated 
that  for some analytes (exemplarily shown for IL-6 and  E-Selectin) an  incubation time  of 2 h is 
sufficient to allow sensitive and accurate quantification. For some analytes (exemplarily S-100 and 
CRP) shortening of the incubation time to 2 h accounts for decreased sensitivity calling for variation of 
the incubation time according to the requirements with respect to assay sensitivity and assay time. The 
establishment of an internal calibration makes the protein chip even more attractive for point-of-care 
applications since it further simplifies the device in terms of quality control and handling. The low 
volume protein-chip allows accurate determination of the sepsis biomarkers with good reproducibility 
(CV < 14%). Recoveries are within the clinically acceptable range (70–130%).  
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